Indefinite Delivery Contract SPE2DU25D9532

The federal contract IDV award to DMS Pharmaceutical Group Inc. is a single-award Indefinite Delivery Contract (IDC) with the Defense Logistics Agency (DLA) under the SPE2DB program, valued at $499,999,999 and valid through November 2026. This IDC enables the DLA to issue firm fixed-price delivery orders for a comprehensive range of pharmaceutical items, including branded and generic prescription drugs, over-the-counter medications, biologics, and medical consumables, to support the medical supply needs of military health facilities worldwide. The contract covers various product categories such as injections, tablets, creams, auto-injectors, and specialty medications, positioning DMS Pharmaceutical Group as a crucial supplier in the federal pharmaceutical supply chain and providing direct distribution of prescription drugs and pharmacy services to Department of Defense healthcare sites.

The IDC is part of the DLA Troop Support Medical Supply Chain's broader Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) procurement, which aims to establish multiple Prime Vendor Contracts to provide worldwide pharmaceutical support to various Department of Defense (DoD) customers, the United States Coast Guard, Designated Providers, Other Government Agencies, and the US Naval Fleet. The solicitation for this procurement, which is expected to be issued in March 2024, will be an unrestricted and fully competitive acquisition with a total estimated value of $30.3 billion across multiple regional awards to at least three different contractors.